Brazil moves to reclassify IVDs with regulatory review consultation
This article was originally published in Clinica
Brazil has put out for open consultation a review of the risk classification of in vitro diagnostic (IVD) products. The proposals feature a series of 13 rules that healthcare regulatory agency Anvisa would use to determine which of four classes a product should be regulated as.
You may also be interested in...
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.